COMPANY

Lumen Bioscience

HQ: Seattle, WA source · lumen.bio ↗ · West Coast

1 open job · last seen Oct 23, 2026 · 15 sources

Keywords: antibody malaria Travelers Diarrhea Clostridioides Difficile Infection Viral Infections Campylobacter Infections COVID-19 C. Diff. Infections Campylobacter Jejuni Infection LMN-101 LMN-201 LMN-1001 LMN-301 LMN-401

Profile checked Oct 10, 2026

Since the raise (Oct 8, 2025): 1 of 1 open job was first seen after it.

1Open jobs $30.0MRaised (2 yrs)8Trials (company is sponsor)5NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Process Engineer II - GMP Equipment Lifecycle	Seattle, WA	Aug 27, 2026	Oct 5, 2026

See all 1 job

Raises and deals from press releases

Raise Series C · $30M · announced Oct 8, 2025 Company release ↗
Source quote
- Oct 8, 2025 · Company release ↗
  “Lumen Bioscience raises $30M Series C extension”

Raises announced in these releases: $30M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 9, 2026 Trial start Phase 1: A Study of Intranasal LMN-1001 in Healthy Adults source ↗
Oct 5, 2026 Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
Oct 8, 2025 Raise Private equity round — Series C extension: $30M (total, as published), announced Oct 8, 2025. Source: company's own press page. source ↗
Oct 8, 2025 Raise Series C · $30M source ↗
Dec 4, 2024 Trial start Early phase 1: G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies source ↗
Aug 29, 2024 Trial start Phase 2/Phase 3: LMN-201 for Prevention of C. Difficile Infection Recurrence source ↗
Jun 20, 2024 Trial start —: Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia source ↗
Oct 6, 2023 Trial start Phase 1: A Study to Determine the Tolerability of Intranasal LMN-301 source ↗
Feb 21, 2022 Trial start Phase 2: LMN-101 in a Campylobacter Human Challenge Model source ↗
Aug 18, 2021 Trial start Phase 1: Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies source ↗
Nov 15, 2019 Trial start Phase 1: Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers source ↗

Upcoming milestones

Jun 6, 2027 (ESTIMATED) · Phase 1 · A Study of Intranasal LMN-1001 in Healthy Adults · NCT07852208

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Process Engineer II - GMP Equipment Lifecycle	Seattle, WA	Aug 27, 2026	Oct 5, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $30.0M. Last 2 years.

Oct 8, 2025 Private equity round — Series C extension: $30M (total, as published), announced Oct 8, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT05330182	LMN-201 for Prevention of C. Difficile Infection Recurrence	Phase 2/Phase 3	Active, not recruiting	Aug 29, 2024	Aug 31, 2026 (actual)
NCT07852208	A Study of Intranasal LMN-1001 in Healthy Adults	Phase 1	Not yet recruiting	Nov 9, 2026	Jun 6, 2027 (estimated)
NCT06363890	Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia	Not listed	Completed	Jun 20, 2024	Mar 1, 2026 (actual)
NCT04182490	LMN-101 in a Campylobacter Human Challenge Model	Phase 2	Completed	Feb 21, 2022	Oct 4, 2022 (actual)
NCT06030414	A Study to Determine the Tolerability of Intranasal LMN-301	Phase 1	Completed	Oct 6, 2023	Dec 28, 2023 (actual)
NCT04893239	Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies	Phase 1	Completed	Aug 18, 2021	Feb 23, 2022 (actual)
NCT04098263	Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers	Phase 1	Completed	Nov 15, 2019	Apr 15, 2020 (actual)
NCT06556940	G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies	Early phase 1	Recruiting	Dec 4, 2024	Oct 2, 2025 (estimated)

NIH awards 5

Annual award amounts. Total $3.5M.

Jun 24, 2024 NIH award 5R42AI138623-05 FY2024: $925,300 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/oral source ↗
Aug 21, 2023 NIH award 5R42AI138623-04 FY2023: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/or source ↗
Jul 19, 2021 NIH award 2R42AI138623-03A1 FY2021: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/ source ↗
Apr 23, 2019 NIH award 5R41AI138623-02 FY2019: $297,071 awarded for that fiscal year; activity R41 (STTR); PI MURPHY, SEAN C; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Development of a Spirulina-based oral malari source ↗
May 16, 2018 NIH award 1R41AI138623-01A1 FY2018: $299,904 awarded for that fiscal year; activity R41 (STTR); PI MURPHY, SEAN C; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Development of a Spirulina-based oral mala source ↗

Connect

See your connections at Lumen Bioscience on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Careers page (Oct 8, 2026)